Introduction
============

Obesity is a well-established risk factor for coronary artery disease and is increasing throughout the developing world.^[@B1],\ [@B2]^ Large population studies have demonstrated an association between obesity and cardiovascular death,^[@B3]^ and the number of obese patients undergoing percutaneous coronary intervention (PCI) is high.^[@B4]^

Despite evidence for risk induced by an elevated body mass index (BMI), recent studies have suggested a paradoxical protective effect of obesity on post-PCI and coronary artery bypass grafting (CABG) mortality, rendering the relation between the BMI and the coronary intervention outcome even more complex.^[@B5],\ [@B6]^

The prevalence of obesity and overweight in the Iranian population has been reported to stand at 11.6% and 38.2%, respectively.^[@B7]^ Obesity is, consequently, regarded as a leading cause of death in Iran.^[@B8]^ The aim of the present study was to determine the relationship between the BMI and the mid-term outcome after PCI in a sample of Iranian population.

Methods
=======

Between March 2006 and August 2008, 4550 PCI procedures were performed at Tehran Heart Center. Complete demographic, procedural, in-hospital, and follow-up information of these patients was registered in the PCI Data Bank of our institution. Patients who underwent PCI on the same day as suffering myocardial infarction (MI) (regarded as primary PCI) were excluded (159 patients). In total, 344 (7.8%) patients were excluded because they failed to return to the hospital for at least one follow-up visit. The mean BMI was 27.48 ± 4.15 kg/m^2^ for the missed patients and 27.62 ± 4.27 kg/m^2^ for the included patients. This study complies with the Declaration of Helsinki, and its research protocol was approved by our institutional Review Board.

The frequency of the patients who completed a follow-up period of 9 months after discharge was more than 95% in all the groups (95.4%, 95.7%, and 95.5% for the normal-weight, overweight, and obese groups, respectively). From the remaining patients, 61 individuals who had unsuccessful PCI and 38 who had missing data on the BMI were also excluded. Finally, a total of 3948 successful coronary interventional procedures were included in the study.

The procedural description and detailed definition of the variables can be found in our previous study.^[@B9],\ [@B10]^ In summary, the patients received 325 mg of Aspirin before the procedure, and coronary stenting was performed by routine methods. Following stent placement, Ticlopidine (250 mg twice daily) or Clopidogrel (75 mg daily) was given for 4 weeks to those with bare-metal stents and for 12 months to the ones with drug-eluting stents. Glycoprotein IIb/IIIa blocker was administered to none of our patients.

After discharge from the hospital, all the patients were monitored by cardiologists at 1, 5, and 9 months post angioplasty, and follow-up was done at our outpatient clinics or by telephone interviews.

The BMI was calculated as weight (kilograms) divided by the square of the individual\'s height in meters (kg/m^2^). Based on the BMI, the study population was divided into normal (BMI \< 25 kg/m^2^), overweight (25 ≤ BMI \< 30 kg/m^2^, and obese (BMI ≥ 30 kg/m^2^) patients. The glomerular filtration rate was calculated via the CKD-EPI formula.^[@B11]^

The in-hospital outcome was evaluated in terms of in-hospital death, in-hospital nonfatal MI, and abrupt closure. Abrupt closure refers to the total occlusion of the dilated artery occurring at any time during the procedure or repeat catheterization before hospital discharge or subtotal occlusion with electrocardiographic evidence of ischemia.

During the 9-month follow-up period, clinical data were recorded. Major adverse cardiac events (MACE), including cardiac death, nonfatal MI, target vessel revascularization (\[TVR\]: repeated PCI or elective CABG), and target lesson revascularization (\[TLR\]: repeat PCI on the same lesion), were recorded during the follow-up period.

The numerical variables are presented as mean ± standard deviation (SD), while the categorical variables are summarized by raw frequencies and percentages. The Kolmogorov-Smirnov test was used to test normal distribution. The continuous variables were compared using the one-way analysis of variance (ANOVA) or the Kruskal-Wallis test when the presumption of normality was not met, and the categorical variables were compared using the chi-squared test or the Fisher exact test (as appropriate), across the three BMI groups.

Multivariable Cox proportional hazards regression models adjusted for age, gender, smoking history, diabetes mellitus, systemic hypertension, PCI on the left anterior descending coronary artery (LAD), hyperlipidemia, and prior ST-elevation MI were established to examine differences in 9 months\' MACE, TVR, TLT, nonfatal MI, and CABG across the BMI groups.

For the statistical analysis, the statistical software SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL) and the statistical package SAS version 9.1 for Windows (SAS Institute Inc., Cary, NC, USA) were used. All the p values were 2-tailed, with statistical significance defined by a p value ≤ 0.05.

Results
=======

The demographic and clinical characteristics of the patients are listed in [Table 1](#T1){ref-type="table"}. There were 1058 patients in the normal BMI, 1867 in the overweight, and 1023 in the obese groups. The patients with a higher BMI were younger and were more likely to be female. Compared to the other groups, the obese group showed a higher frequency of diabetes mellitus and positive family history for coronary artery disease. The obese patients also had a higher mean of the left ventricular ejection fraction. As is shown in [Table 2](#T2){ref-type="table"}, there was no association between the BMI and the angiographic and procedural findings in the univariate analysis.

###### 

Baseline characteristics of the study population based on the BMI categories[^\*^](#TFN1){ref-type="table-fn"}

                                                Normal Weight (n=1058)   Overweight (n=1867)   Obese (n=1023)   P value
  --------------------------------------------- ------------------------ --------------------- ---------------- ----------
  BMI (kg/m^2^)                                 22.79±1.70               27.33±1.37            33.12 ± 3.09     \< 0.001
  Age (y)                                       58.21±10.45              57.00±10.34           56.24±9.78       \< 0.001
  Female                                        217 (20.4)               499 (26.7)            492 (48.1)       \< 0.001
  Smoking history                                                                                               \< 0.001
    Current                                     326 (30.8)               424 (22.8)            166 (16.2)       
    Quitted                                     193 (18.3)               382 (20.46)           149 (14.6)       
    No history                                  538 (50.9)               1056 (56.7)           707 (69.02)      
  Diabetes mellitus                             213 (20.1)               459 (24.6)            325 (31.8)       \< 0.001
  Systemic hypertension                         360 (34.0)               842 (45.2)            569 (55.6)       \< 0.001
  Hyperlipidemia                                640 (60.5)               1335 (71.8)           778 (76.1)       \< 0.001
  Positive family history                       242 (23.0)               484 (26.0)            265 (26.1)       0.140
  Renal failure                                 108 (10.4)               237 (12.9)            113 (11.2)       0.111
  Prior STEMI                                   336 (31.8)               531 (28.5)            249 (24.5)       0.001
  Acute coronary syndrome in recent one month   278 (26.3)               481 (25.8)            250 (24.4)       0.606
  Cholesterol (mg/dl)                           174.41±48.29             172.94±48.37          179.90±49.60     0.001
  Triglyceride (mg/dl)                          161.80±92.53             182.80±98.39          194.05±105.34    \< 0.001
  LDL (mg/dl)                                   100.24±38.65             96.10±38.95           100.06±41.56     0.002
  HDL (mg/dl)                                   42.36±11.74              41.23±12.77           41.54±10.28      0.051
  FBS (mg/dl)                                   109.40±45.54             111.27±41.59          120.00±47.55     \< 0.001
  Creatinine (mg/dl)                            1.15±0.35                1.19±0.62             1.18±1.36        0.369
  Ejection fraction                             51.23±9.78               52.86±9.50            52.94±8.93       \< 0.001
  Use of beta blockers                          865 (81.8)               1574 (84.5)           860 (84.3)       0.141
  Use of ACE inhibitors                         477 (45.1)               834 (44.8)            430 (42.2)       0.308

Data are presented as mean±SD or n (%)

BMI, Body mass index; STEMI, ST-elevation myocardial infarction; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; FBS, Fasting blood sugar; ACE, Angiotensin-converting enzyme

###### 

Angiographic and procedural characteristics of the study population based on the BMI categories[^\*^](#TFN3){ref-type="table-fn"}

                                   Normal Weight (n=1058)   Overweight (n=1867)   Obese (n=1023)   P value
  -------------------------------- ------------------------ --------------------- ---------------- ---------
  Target coronary artery                                                                           
    LAD or its branches            693 (65.5)               1215 (65.1)           679 (66.4)       0.782
    LCX or its branches            152 (14.4)               308 (16.5)            147 (14.7)       0.180
    RCA or its branches            312 (29.5)               504 (27.0)            283 (27.7)       0.348
    LM                             4 (0.4)                  3 (0.2)               3 (0.3)          0.513
  Severity of CAD                                                                                  0.167
    One-vessel disease             467 (44.1)               767 (42.3)            419 (42.5)       
    Two-vessel disease             424 (40.1)               706 (37.8)            401 (39.2)       
    Three-vessel disease           167 (15.8)               364 (19.5)            184 (18.0)       
  Stent type                                                                                       0.271
    Bare-metal                     368 (34.8)               638 (34.2)            359 (35.1)       
    Drug-eluting stents            679 (64.2)               1210 (64.9)           645 (63.1)       
    Balloon                        10 (0.9)                 17 (0.9)              18 (1.80)        
  Reference vessel diameter (mm)   3.16±0.42                3.21±0.57             3.21±0.47        0.051
  Multi-vessel PCI                 224 (21.2)               450 (24.1)            244 (23.9)       0.171
  Multi-session PCI                58 (5.5)                 125 (6.7)             71 (6.9)         0.326
  Mean lesion length (mm)          22.06±10.64              21.51±9.24            21.75±10.32      0.344
  Mean stent length (mm)           23.48±6.83               23.56±6.68            23.51±6.79       0.946

Data are presented as mean±SD or n (%)

BMI, Body mass index (kg/m^2^); LAD, Left anterior descending coronary artery; LCX, Left Circumflex coronary artery; RCA, Right coronary artery; LM, Left main coronary artery; CAD, Coronary artery disease; PCI, Percutaneous coronary intervention

There were no significant differences in terms of in-hospital death and nonfatal MI between the BMI groups. The overall frequency of in-hospital death was 2 (0.1%). The rates of in-hospital deaths in the normal-weight, overweight, and obese groups were 0%, 0.1%, and 0.1%, respectively. While 1 (0.1%) nonfatal MI was observed in the normal-weight patients, 8 (0.4%) patients in the overweight and 3 (0.3%) patients in the obese groups had in-hospital nonfatal MI ([Table 3](#T3){ref-type="table"}). The incidence of in-hospital emergent cardiac surgery in the obese patients was significantly different from that of the other groups (0.3% in the obese group vs. 0% in the normal-weight group and 0% in the overweight group; p value = 0.01). Abrupt closure occurred more frequently in the overweight patients (0.2%), with no remarkable difference from that in the normal (0%) and obese (0.1%) groups.

###### 

Comparison between the three BMI categories according to in-hospital events[^\*^](#TFN5){ref-type="table-fn"}

                      Normal Weight (n=1058)   Overweight (n=1867)   Obese (n=1023)   P value
  ------------------- ------------------------ --------------------- ---------------- ---------
  In-hospital death   0                        1 (0.1)               1 (0.1)          0.746
  In-hospital MI      1 (0.1)                  8 (0.4)               3 (0.3)          0.316
  Abrupt closure      0                        3 (0.2)               1 (0.1)          0.700

Data are presented as n (%)

BMI, Body mass index; MI, Myocardial infarction

Because the incidence of this complication was very low, a logistic regression analysis for the in-hospital emergent cardiac surgery was not performed, as this could have yielded non-meaningful results. Whereas none of the patients in the normal-weight and overweight groups had in-hospital cardiac arrest, 2 obese patients suffered cardiac arrest (p value = 0.06).

Follow-up analysis
------------------

The prevalence of the patients with MACE after discharge was 2.3% (92 patients). The number of deaths at follow-up was 9 (0.2%): 3 (0.3%) in the normal-weight; 4 (0.2%) in the overweight; and 2 (0.2%) in the obese groups. The Kaplan-Meier survival curve with respect to the three BMI study groups is presented in [Figure 1](#F1){ref-type="fig"}. The figure shows that the survival rate for each group decreased slightly, although this reduction did not reach a statistically significant difference between the BMI groups.

![Kaplan-Meier survival curves based on the body mass index categorization, divided as normal (\< 25 kg/m^2^), overweight (≥ 25 to \< 30 kg/m^2^), and obese (≥ 30 kg/m^2^), during a 9-month follow-up period](JTHC-10-18f1){#F1}

The occurrence rates of MACE during the follow-up period either in absolute term or in each of the subcategories (nonfatal MI, TLR, and TVR) are shown in [Table 4](#T4){ref-type="table"}. Although the rate of MACE rose as the BMI increased, it did not reach a statistically significant level. Additionally, the number of the individuals undergoing CABG during the follow-up period was 2 (0.2%), 10 (0.5%), and 5 (0.5%) in the normal-weight, overweight, and obese groups, respectively (p value = 0.358).

###### 

Comparison between the three BMI categories according to total 9 months\' MACE[^\*^](#TFN7){ref-type="table-fn"}

                                 Normal Weight (n=1058)   Overweight (n=1867)   Obese (n=1023)   P value
  ------------------------------ ------------------------ --------------------- ---------------- ---------
  Number of patients with MACE   19 (1.8)                 46 (2.5)              29 (2.8)         0.248
  Nonfatal MI                    9 (0.9)                  19 (1.0)              12 (1.2)         0.744
  TVR                            8 (0.8)                  32 (1.7)              18 (1.8)         0.072
  TLR                            5 (0.5)                  13 (0.7)              10 (1.0)         0.374
  CABG                           2 (0.2)                  10 (0.5)              5 (0.5)          0.358
  Cardiac death                  3 (0.3)                  4 (0.2)               2 (0.2)          0.880

Data are presented as n (%)

BMI, Body mass index; MACE, Major adverse cardiac events; MI, Myocardial infarction; TVR, Target vessel revascularization; TLR, Target lesion revascularization

We performed multivariate analysis to adjust for clinical and procedural characteristics, including age, gender, smoking history, diabetes mellitus, systemic hypertension, PCI on the LAD, hyperlipidemia, and prior ST-segment elevation myocardial infarction (STEMI). After adjustment, there was no significant difference in terms of MACE between the three groups (p value = 0.603). Moreover, no significant difference was observed in TVR and TLR between the BMI groups (p value = 0.226 and p value = 0.724, respectively). The rate of nonfatal MI was not different between the three groups after adjustment for the above variables (p value = 0.836). The number of the individuals undergoing CABG was significantly different between the BMI groups before adjustment, while no remarkable difference was observed after adjustment (p value = 0.682).

Discussion
==========

Our study showed that the occurrence of MACE was not significantly different between the BMI groups undergoing PCI after a follow-up period of 9 months. Moreover, there was an increasing trend of in-hospital outcomes such as cardiac death and emergent cardiac surgery in the obese individuals in the Iranian population.

To our knowledge, the present study is the first of its kind to aim at evaluating the effect of the BMI on mortality in patients undergoing successful elective PCI in the Iranian population. Several studies have reported a relationship between severe obesity and worse in-hospital outcomes after PCI. Ellis et al.^[@B12]^ found that patients with BMI \> 35 kg/m^2^ had higher in-hospital mortality as well as those with BMI \< 18.5 kg/m^2^. A similar relation was found by Powell et al.^[@B13]^ between mortality and extreme BMI after PCI. In our study, increased in-hospital outcomes in the obese patients were similar to those in the above studies. Be that as it may, a lack of underweight and severely obese participants meant that comparisons in our study were made between only three BMI groups: normal weight, overweight, and obese. It has been documented that in patients undergoing coronary revascularization (either bypass surgery or PCI) after acute MI, those with morbid obesity (BMI ≥ 40 kg/m^2^) have lower odds of in-hospital mortality compared to non-morbidly obese patients.^[@B14]^ Patients with acute MI were excluded from this study. Based on the Cadillac study by Nikolski et al.,^[@B15],\ [@B16]^ there is a correlation between lower mortality and higher BMI.^[@B13],\ [@B15]^ A study conducted by Curtis et al.^[@B17]^ revealed the protective effects of obesity on short-term and long-term mortality after PCI, which supports the existence of the obesity paradox. In contrast, among the studies with longer follow-up periods, the BARI trial, Bypass Angioplasty Revascularization Investigation by Gurm et al.,^[@B6]^ and ARTS trial by Gruberg et al.^[@B4],\ [@B5]^ showed no difference in long-term mortality in obese individuals compared to other groups. In addition, Tarastchuk et al.^[@B18]^ found no effect of the BMI on short-term mortality in PCI patients, while waist circumference was an independent predictor of MACE. The most recent study is one conducted by Sarno et al.,^[@B19]^ who reported that after 1-year follow-up, the cumulative rate of cardiac death, MI, and clinically justified TVR was significantly higher in the obese group and that a higher BMI was an independent predictor of stent thrombosis.

In a meta-analysis of studies on the effect of obesity on short- and long-term mortality after coronary revascularization,^[@B20]^ compared to individuals with non-elevated BMI levels, obese patients undergoing PCI had lower short- and long-term mortality. This study suggested that further research was needed to confirm the validity of these findings. Subsequently, Hastie et al.^[@B21]^ studied a cohort of 4880 patients undergoing PCI and reported that, compared with normal-weight patients, only a subgroup of patients categorized as overweight II patients (27.5 ≤ BMI \< 30 kg/m^2^) had a reduced risk of dying after 5 years\' follow-up either after the procedure or 30 days after the procedure. In their study, risk of death was similar when the normal-weight patients were compared with overweight I (25 ≤ BMI \< 27.5 kg/m^2^) and obese (BMI ≥ 30 kg/m^2^) cases. Our overweight (25 ≤ BMI \< 30 kg/m^2^) and obese patients had similar mid-term cardiac mortality compared to the normal-weight group. The results of our study, with an about 2.5-fold larger study sample, are consistent with the results of the Poston et al.^[@B22]^ study, which reported no protection afforded by obesity against cardiac events 6 months after PCI. However, this result can still be considered the obesity paradox as one would expect that a higher BMI would indicate an increased risk of cardiac mortality after PCI.

This is a retrospective study and, thus, suffers from all the limitations inherent in studies of its kind. There were only 35 underweight and severely obese patients in our ample population, which precluded separate analysis. The non-inclusion of waist and hip circumferences in the analysis, which should be analyzed as an index of central obesity, is one of the limitations of our study.

Conclusion
==========

We found that the BMI status was not a significant predictor of MACE at a 9-month follow-up period among patients having undergone PCI. It seems that the BMI should not have a significant effect on the clinicians' therapeutic recommendations for such patients.
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